AUSTIN, Texas– Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells (BM-MSCs) to address multiple disease indications, announces favorable safety data and significant efficacy results from its Phase 2 clinical trial (NCT04493242) of ExoFlo™ in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). [Read more…]
How Topical Application of Stem Cell Serum Can Reverse COVID-Induced Hair Loss
What is Covid-related hair loss?
Covid-19 is said to cause long-term side effects in up to 67% of patients, and these health consequences can include chronic fatigue, loss of taste and smell and brain fog. Increasingly common too is Covid-related hair loss. Known as telogen effluvium, this phenomenon manifests as clumps of hair falling out after brushing or washing your hair. [Read more…]
StemBioSys Launches CELLvo™, Human iPSC-Derived Atrial Cardiomyocytes for Cardiotoxicity Screening
Developed in collaboration with REPROCELL, CELLvo™Â Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells
SAN ANTONIO, June 13, 2023 — StemBioSys, Inc. (StemBioSys) announced the launch of CELLvo™Â Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to function identically to human atrial cardiomyocytes. StemBioSys developed CELLvo™Â Atrial Cardiomyocyte to empower pharmaceutical companies and academics with a more precise, efficient and cost-effective platform for screening new drug products in vitro for cardiotoxicity compared to animal models and other in-vitro methods currently in use. [Read more…]
Saint-Gobain Life Sciences and denovoMATRIX announce investment and expansion of service agreement
DRESDEN, Germany, 20 June, 2023 – denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, and Saint-Gobain Life Sciences have expanded their Master Service Agreement with a special focus on products related to the Stem Cell therapy market. At the same time, Saint-Gobain Life Sciences’ investment arm NOVA announces its strategic investment into denovoMATRIX. [Read more…]
Celularity – Big Bucks, Billionaire Investors, Bold Dreams
Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 334
- Next Page »